Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 pharmacokinetics in renal impairment
NCT05718648Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nerandomilast (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 144 hours, Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 144 hours and 2 more. Started Feb 2023; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT05718648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718648.